Sovaldi pill. Source: Gilead SciencesGilead Sciences had another phenomenal year in 2014, returning 26% for investors. That’s more than double the return of the broad-based S&P 500 , and it has hepatitis C drug Sovaldi to thank.In just the first nine months of 2014, Sovaldi netted Gilead $8.55 billion in sales. It’s the most effective drug launch in history by […]
Source: StockMonkeys.com via Flickr.It’s been a truly transformative year for Gilead Sciences and its shareholders. Even taking into consideration the latest swoon in Gilead’s share price tied to the approval of AbbVie ‘s Viekira Pak and its subsequent multi-year agreement with Express Scripts , Gilead shares are up 25% for the year, essentially doubling the return of the S&P 500 […]
View gallery.It’s been a rough couple of days for biotech stocks.To start, Gilead Sciences, Inc. (NASDAQ: GILD) has dropped from a high of almost $110 per share on Friday to a low of $86 on Tuesday.Many other big-name biotechs, such as Amgen, Inc. (NASDAQ: AMGN), Biogen Idec Inc (NASDAQ: BIIB) and Valeant Pharmaceuticals Intl Inc (NYSE: VRX) have fallen with […]
Source: MercK & Co.,Just when it looked as though the stock market couldn’t possibly finish the year higher, after its swoon in October, it proved the naysayers wrong. As of this writing, the S&P 500 has risen by 11% for the year, a tad bit higher than the stock markets’ historic annual return.But if you think that’s a solid return, […]
Source: Celgene CorporationThe biotechnology industry has been one of the best performing baskets in the stock market this year, but just because biotech stocks were kind to investors this year doesn’t necessarily mean that they’ll rally next year, too.Biotech stocks can move significantly higher or lower in any given year due to investor’s reaction to data from ongoing drug trials, […]
Biotechnology stocks have been among the market’s top performers this year, with the iShares Nasdaq Biotechnology ETF’s 36% gain handily outpacing the S&P 500 ‘s 14% return. That heady return, however, comes with one potential drawback: It might be tough to figure out which biotech stocks will continue climbing next year. With that in mind, here are three large-cap biotech […]
Source: ;Flickr user VastateparksstaffWhen to sell a winning stock is one of the toughest questions for investors to answer. Selling a stock that is reaching for new highs might be the right decision sometimes, but other times it might mean getting out of a long-haul opportunity too early. With that in mind, we asked three Motley Fool analysts to tell […]
PundingTyco worldwide ltd Stocks talked about Ralph lauren polo sport woman in the in depth session of jim cramer mad money tv program, wed, june 14. Good buy at the most suitable price ralph lauren(Rl), Jones ralph lauren jackets accessories(Jny), Orbital Sciences(Orb), Tyco(Tyc) Ralph lauren will be stock that cramer wants investors to buy but only at the right price.All […]
Big Data focus for UniversityEdinburgh’s expertise in handling Big Data is to be strengthened with the appointment of medical informatics expert Professor Andrew Morris.His appointment as the University’s new Vice-Principal of Data Science will see him work closely with colleagues to create cross-disciplinary opportunities for education, research and innovation in the field.Professor Morris will advise the Principal and senior management […]
Wanna know what the most popular movies, albums and video games are? Ask the internet. But don’t Google it. Check what other people Googled. That’s the theory behind Google Flu Trends—which crunches search data to forecast flu prevalence. With admittedly mixed results.Nevertheless, researchers have applied the idea to the stock market. They found that when searches related to business and […]
